Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
Oculis Holding AG said its management team will participate in upcoming investor conferences in April, providing updates on the company’s late-stage ophthalmic and neuro-ophthalmic pipeline.
Needham Healthcare Conference
April 13-16, Virtual
Company presentation: April 14, 9:30 AM ET
Webcast link: posted on the Oculis website under the Investors & Media section when available.
Van Lanschot Kempen Life Sciences Conference
April 15-16, Amsterdam, Netherlands
Oculis management will hold one-on-one meetings.
The company said investors interested in one-on-one meetings should contact their respective representative at the sponsoring institutions to request appointments. Webcast links, when available, will be posted on the Oculis website on the Events & Presentation page.
Oculis said 2026 is a “landmark year” as it works to transform into a leader in neuro-ophthalmology and ophthalmology. Key updates cited by the company include:
Oculis said it has a “strong balance sheet” and “robust pipeline,” and that it is positioned to deliver six pivotal readouts with its current funding.
Oculis is a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology. The company’s late-stage clinical pipeline includes three core product candidates:
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
The company said the press release contains forward-looking statements, including statements regarding development plans, clinical trial timing and results, regulatory and business strategy, future development plans, market opportunity, and cash runway. Oculis noted that such statements are subject to risks and uncertainties, including those described in the Risk Factors section of its annual report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Oculis said it does not undertake an obligation to update these statements except as required by law.

Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…